Efficacy of Edaravone in Combination with Dihydropyridine Calcium Ion Antagonist on Hypertensive Intracerebral Hemorrhage

Abstract

This research article planned to investigate the efficacy of edaravone in combination with dihydropyridine calcium ion antagonist on hypertensive intracerebral hemorrhage. Between February 2017 and January 2019, we collected the clinical data from 126 hypertensive intracerebral hemorrhage patients and divided them into the control group and observation group, with 63 patients in each group. Patients in two groups all underwent the regular treatment, while those in the observation group took edaravone in combination with dihydropyridine calcium ion antagonist (nimodipine) for treatment. Following the treatment, we compared the clinical efficacy, plasmin endothelin 1, volume of edema and hematoma and National Institute of Health stroke scale scores. In the control group, the total effectiveness rate of treatment was 71.44 %, significantly lower than that of the observation group (p<0.05); following treatment, the level of endothelin 1 in plasma and the volumes of edema and hematoma were all decreased as compared to those before treatment and the decrease in the observation group was more evident (p<0.01). Before treatment, difference in the National Institute of Health stroke scale scores between the control group and the observation group was not evident (p>0.05), while after 2 and 4 w of treatment, patients in the observation group had scores of (12.43±4.07) and (7.52±1.84) points, significantly higher than those in the control group (p<0.01). Combined medication of edaravone and dihydropyridine calcium ion antagonist can benefit the patients with promising efficacy and improvement in nervous function.